DGAP-News: Apricus Bio CEO to Present Commercialization Plans for Vitaros(R) at Jefferies 2011 Global Healthcare Conference

Apricus Biosciences, Inc.

03.06.2011 16:17
—————————————————————————

Company Presentation Moved to June 8, 2011 at 2:00pm ET

SAN DIEGO, 2011-06-03 16:17 CEST (GLOBE NEWSWIRE) —
Bassam Damaj, PhD., Chief Executive Officer of Apricus Biosciences, Inc.
(–Apricus Bio–) (Nasdaq:APRI) (http://www.apricusbio.com) announced today that
he will discuss plans for the commercialization of Vitaros(r), the Company–s
topical erectile dysfunction drug, during his presentation at the Jefferies
2011 Global Healthcare Conference. Dr. Damaj–s presentation date and time have
been changed, and will now take place on June 8, 2011 at 2:00pm, at the Grand
Hyatt Hotel in New York.

Vitaros(r) is approved for sale in Canada and is expected to be on the market in
that country during the second half of 2011. Dr. Damaj will also review the
Company–s recent marketing application filing for Vitaros(r) in Europe, as well
as expectations for filing a marketing application in Switzerland. Vitaros(r)
utilizes Apricus Bio–s NexACT(r) drug delivery technology, which enables the
rapid absorption of various active pharmaceutical ingredients through the skin,
with the goal of improving patient outcomes and reducing side effects.

Dr. Damaj–s presentation at the Jefferies conference will be webcast and
accessible to the public online at http://www.wsw.com/webcast/jeff60/apri/ or
via the Apricus Bio–s web site at http://www.apricusbio.com. A replay will be
available for 90 days after the presentation.

Other drugs in Apricus Bio–s pipeline include: Femprox(r), a treatment for female
sexual arousal disorder; MycoVa?, for onychomycosis (nail fungus); PrevOnco?, a
treatment for hepatocellular liver carcinoma; and RayVa?, for Raynaud–s
Syndrome.

About Apricus Biosciences, Inc.

Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has
leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes.

Revenues and growth are driven from out-licensing of this technology for the
development and commercialization of such compounds to pharmaceutical and
biotechnology companies worldwide. In addition, the Company is seeking to
monetize its existing product pipeline, including its first product, Vitaros(r),
approved in Canada for the treatment of erectile dysfunction, which is
currently expected to be available on the Canadian market in 2011, as well as
compounds in development from pre-clinical through Phase III, currently focused
on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain,
Anti-Infectives, Diabetes and Cosmeceuticals among others.

For further information on Apricus Bio, visit http://www.apricusbio.com and for
information on its subsidiaries please visit www.nexmedusa.com or
www.bio-quant.com. You can also receive information at
http://twitter.com/apricusbio and http://facebook.com/apricusbio.

Apricus Bio–s Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact thematters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further development products and
product candidates, have such products and product candidates approved by
relevant regulatory authorities, to successfully commercialize such products
and product candidates and to achieve its other development, commercialization
and financial goals. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the risk
factors set forth in the Company–s most recent annual report on Form 10-K,
subsequent quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC–s website or without
charge from the Company.

CONTACT: Apricus Biosciences, Inc.
Edward Cox, V.P.
Corporate Development&Investor Relations
(858) 848-4249
ecox@apricusbio.com

Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX

03.06.2011 Dissemination of a Corporate News, transmitted by DGAP –
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP–s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

—————————————————————————

Language: English
Company: Apricus Biosciences, Inc.

United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:

End of Announcement DGAP News-Service

—————————————————————————